Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma

June 28th 2022

The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.

Venetoclax and HMA Resistance in Patients with AML

June 28th 2022

Dr Daniel Pollyea discusses the role of venetoclax plus an HMA agent in patients with AML and talks about some possible mechanisms of resistance to the venetoclax-HMA combination.

Teclistamab Elicits Survival Benefit vs Real-World Treatment in Multiple Myeloma

June 28th 2022

Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.

Potential Role of Tamibarotene in AML

June 28th 2022

Daniel Pollyea, MD, MS, reviews the initial results from the biomarker-directed phase 2 tamibarotene trial that were presented at ASH 2020.

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCL

June 27th 2022

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

June 24th 2022

The FDA has approved lisocabtagene maraleucel as second-line therapy for adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Asciminib Moves Toward EU Approval for Ph+ CML in Chronic Phase

June 24th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization for asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who were previously treated with at least 2 TKIs.

CHMP Recommends Melphalan Flufenamide for Triple-Class Refractory Multiple Myeloma

June 23rd 2022

The European Medicines Agency's Committee for Medicinal Products for Human Use has unanimously recommended full marketing authorization approval of melphalan flufenamide for patients with triple-class refractory multiple myeloma.

Unmet Needs and Future Perspectives in AML

June 23rd 2022

Richard Stone, MD, and Eunice Wang, MD, share upcoming treatment advances they look forward to for patients with acute myeloid leukemia (AML).

Targeted Therapy in Patients with AML and IDH1/IDH2 Mutations

June 23rd 2022

An overview of treatment options in patients who present with IDH1/IDH2 mutations and how to manage treatment-related adverse events.

Crenolanib Plus Chemotherapy Provides Long-Term Survival Benefit in FLT3-Mutant AML

June 23rd 2022

Eunice Wang, MD, discusses the long-term results of a phase 2 trial investigating crenolanib plus chemotherapy in adult patients with newly diagnosed FLT3-mutant acute myeloid leukemia.

FDA Grants Orphan Drug Designation to MB-106 for Waldenström Macroglobulinemia

June 22nd 2022

The FDA has granted an orphan drug designation to the CD20-targeted autologous CAR T-cell therapy, MB-106, for use as a potential therapeutic option in patients with Waldenström macroglobulinemia.

Talquetamab Monotherapy Shows Early Promise in Relapsed/Refractory Multiple Myeloma

June 22nd 2022

Monique Minnema, MD, discusses the rationale of the MonumenTAL-1 trial examining talquetamab in multiple myeloma, the safety and efficacy reported thus far with the bispecific antibody, and next steps for further exploration.

Guadecitabine Fails to Improve OS Over Physician’s Choice of Treatment in MDS and CMML

June 21st 2022

Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.

Nemtabrutinib Generates Responses, Displays Manageable Safety in CLL/SLL

June 20th 2022

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

European Medicines Agency Validates Type II Variation Application for Liso-cel in Second-line LBCL

June 20th 2022

The European Medicines Agency has verified its type II variation application to extend the indication for lisocabtagene maraleucel to include the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma, who are refractory or have relapsed within 12 months of initial therapy and are candidates for hematopoietic stem cell transplant.

Biomarker Testing in AML

June 17th 2022

Dr Daniel Pollyea comments on biomarker testing in acute myeloid leukemia and the potential role for RARA testing.

Treatment Options for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

June 17th 2022

A review of treatment options for patients with newly diagnosed acute myeloid leukemia and differences between patients who are fit vs unfit for chemotherapy.

Importance of Molecular Testing in Acute Myeloid Leukemia to Guide Treatment

June 16th 2022

Richard Stone, MD, and Eunice Wang, MD, explain how molecular biomarker testing influences their treatment decision-making in patients with acute myeloid leukemia (AML).